Back to Results
First PageMeta Content
Implants / Circulatory system / Neuroprosthetics / Heart diseases / Prosthetics / Artificial cardiac pacemaker / Implanted cardiac resynchronization device / Heart failure / Implantable cardioverter-defibrillator / Medicine / Cardiac electrophysiology / Biology


REVERSE & RAFT - FDA Executive Summary
Add to Reading List

Open Document

File Size: 761,38 KB

Share Result on Facebook

Company

Medtronic / Tang A. S. / Previous HF / New England Journal / Boston Scientific / Combined HF / Hospitalization Subgroup / REVERSE & RAFT Studies FDA / /

Continent

Europe / /

Country

Turkey / United States / Canada / Australia / /

Currency

pence / /

Event

FDA Phase / Force Majeure / /

Facility

Hall WJ / University of Ottawa Heart Institute-sponsored RAFT / /

IndustryTerm

treatment of chronic heart failure / treatment of heart failure / /

MedicalCondition

severe heart failure / either heart failure / ventricular tachycardia / vEntricular dysfunction / advanced chronic heart failure / sudden cardiac death / bundle branch block / chronic heart failure / Cardiac Failure / Ventricular tachyarrhythmia therapy / heart failure / ventricular fibrillation / mildly symptomatic heart failure / ventricular tachyarrhythmia / mild-to-moderate heart failure / /

MedicalTreatment

Cardiac Resynchronization Therapy / /

Organization

University of Ottawa Heart Institute-sponsored RAFT / Food and Drug Administration / Center for Devices and Radiological Health / New York Heart Association / FDA / Division of Cardiovascular Devices / /

Position

Executive / /

Product

CRT / Baseline Heart Failure Medication / D274TRK / Medtronic CRT / D284TRK / S125 / C154DWK / D334TRG / D224DRK / S171 / /

PublishedMedium

New England Journal of Medicine / /

Region

Western Europe / New England / /

Technology

28 6.6 Protocol / 51 8.7 Protocol / /

SocialTag